Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.76 |
| ▸ | FNTB | P49356 | 16/20 | 0.76 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5513838 | 0.89 | FNTA (0.60) | FNTAFNTBPGGT1B | |
| SCHEMBL4372438 | 0.86 | FNTA (1.00) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL5556203 | 0.83 | FNTA (0.69) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL4381345 | 0.77 | FNTA (0.83) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL13501477 | 0.76 | FNTA (0.62) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL13501489 | 0.76 | FNTA (0.62) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL4373656 | 0.76 | FNTA (0.82) | FNTAFNTBPGGT1B | |
| SCHEMBL4372103 | 0.76 | FNTA (1.00) | FNTAFNTBPGGT1B | |
| SCHEMBL6841549 | 0.76 | FNTA (0.46) | FNTAFNTBPGGT1B | |
| SCHEMBL13501594 | 0.76 | FNTA (0.59) | FNTAFNTBPGGT1BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063770-A1 | Method for treating Alzheimer's disease | WARNER-LAMBERT COMPANY | 2004-04-01 | — | — | US | claimed |
| US-20010051642-A1 | Method for treating Alzheimer's disease | AHN KYUNGHYE (US) | 2001-12-13 | — | — | US | claimed |
| US-20040063770-A1 | Method for treating Alzheimer's disease | WARNER-LAMBERT COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-20010051642-A1 | Method for treating Alzheimer's disease | AHN KYUNGHYE (US) | 2001-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063770-A1 | Method for treating Alzheimer's disease | BACE1, BACE2, PSEN1 | FNTA 15/4885FNTB 31/4885PGGT1B 232/4885 |
| US-20010051642-A1 | Method for treating Alzheimer's disease | BACE1, BACE2, PSEN1 | FNTA 15/4885FNTB 31/4885PGGT1B 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.